Sophia Umansky—the daughter of Kyle Richards and Mauricio Umansky—doubled down on her decision to take Mounjaro, despite ...

Eli Lilly and Company's Zepbound demonstrated superior weight reduction compared to Novo Nordisk's Wegovy in a 72-week ...

Novo Nordisk now forecasts 2025 sales growth between ... Eli Lilly. Demand for GLP-1 weight-loss drugs surged throughout 2024, significantly outpacing supply. Under US Food and Drug Administration ...

The Trump administration on Monday singled out powerful new weight-loss drugs including Wegovy and Zepbound as targets in its ...

Novo Nordisk shares jumped following stronger-than-expected first-quarter earnings, despite the company lowering its growth outlook for 2025 amid intensifying competition in the weight-loss drug ...

Digital programs incorporating behavioral therapy led to solid reductions in body weight, and did so at lower drug doses.

Makers of weight-loss drugs, the hottest segment of the pharmaceutical market just now, weren't looking so hot on the stock exchange Tuesday. A pronouncement from President Trump about the category ...

A new study shows that people Zepbound lost about 50% more weight than those using Wegovy. It was the first head-to-head ...

While the primary target for these medication is weight loss, it’s not the only metric by which the drugs should be evaluated ...

Novo Nordisk's (NVO) investors are worried its ... Novo also scored an exclusive deal to be listed as the preferred weight-loss drug for coverage on CVS's (CVS) formulary. This caused Lilly's ...

Also Read: CVS Caremark To Place Novo Nordisk’s Wegovy On Preferred Coverage For GLP-1 Weight Loss Treatment Insulin sales increased 4% to 14.9 billion Danish kroner, and Rare disease sales ...